Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834274 · ClinicalTrials.gov registry record · Phase 3
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT01834274 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 96 participants.
The verdict
NCT01834274, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Sitagliptin Placebo
- DRUG Fasiglifam (TAK-875)
- DRUG Fasiglifam (TAK-875) Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834274
The ClinicalTrials.gov registry entry for NCT01834274 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT01834274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834274 about?
NCT01834274 is a clinical study titled "Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
What is the current status of trial NCT01834274?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2013-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01834274?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), Sitagliptin Placebo (DRUG), Fasiglifam (TAK-875) (DRUG), Fasiglifam (TAK-875) Placebo (DRUG).
Who is sponsoring clinical trial NCT01834274?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.